Orforglipron without an injection Foundayo Oral GLP-1 Weight Loss Tablets: W8MD Guide Foundayo is an FDA-approved once-daily oral GLP-1 receptor agonist for chronic weight management in qualifying adults and may be taken with or without food. Contact W8MD What is Foundayo? Foundayo is the brand name for orforglipron, a nonpeptide GLP-1 receptor agonist tablet approved in 2026. It is used with reduced-calorie nutrition and increased physical activity in adults with obesity or overweight plus at least one weight-related condition. The labeled starting dose is 0.8 mg daily, followed after at least 30 days by 2.5 mg and then 5.5 mg. Further increases to 9, 14.5 or 17.2 mg depend on response and tolerability. Tablets are swallowed whole and may be taken with or without food. W8MD original image, used with permission. View the source image . Results and safety In the 72-week approval trial without diabetes, mean loss ranged from 7.4% with 5.5 mg to 11.1% with 17.2 mg, versus 2.1% with placeb...
W8MD is a physician supervised, non-surgical medical weight loss program available in many states including New York, Philadelphia, and Connecticut. Most W8MD medical weight loss locations accept health insurance for the weight loss physician weights!